Covered recipient · General Payments record
TARA M GRAFF
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$138,235.54
142 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $97,914.40 | 38 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,952.50 | 16 |
| Food and Beverage | $4,963.08 | 68 |
| Travel and Lodging | $4,395.91 | 19 |
| Education | $9.65 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $37,272.08 | 32 |
| Genmab U.S., Inc. | $19,761.27 | 32 |
| AstraZeneca Pharmaceuticals LP | $18,506.66 | 14 |
| Incyte Corporation | $14,509.92 | 10 |
| Genentech USA, Inc. | $11,974.65 | 18 |
| Janssen Research & Development, LLC | $10,500.00 | 1 |
| BeOne Medicines USA, Inc. | $10,162.35 | 10 |
| Lilly USA, LLC | $6,695.50 | 4 |
| E.R. Squibb & Sons, L.L.C. | $3,973.32 | 5 |
| AstraZeneca UK Limited | $3,280.00 | 2 |
| PFIZER INC. | $720.00 | 2 |
| Caris MPI, Inc. | $248.16 | 2 |
| ADC THERAPEUTICS AMERICA, INC. | $201.88 | 3 |
| Genentech, Inc. | $173.17 | 2 |
| Celgene Corporation | $124.43 | 3 |
| Adaptive Biotechnologies Corporation | $81.82 | 1 |
| GENZYME CORPORATION | $50.33 | 1 |
Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TARA M GRAFF
NPI 1356584080 · CMS profile ID 1308501
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
CLIVE, IA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356584080?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TARA M GRAFF, NPI 1356584080, CMS profile ID 1308501. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356584080?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). TARA M GRAFF, NPI 1356584080, CMS profile ID 1308501. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356584080?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- TARA M GRAFF, NPI 1356584080, CMS profile ID 1308501, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1356584080?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
142 matching records · $138,235.54 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 142.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genmab U.S., Inc. | $456.97 | 10/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928711 | CMS |
| BeOne Medicines USA, Inc. | $118.13 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202902360 | CMS |
| ABBVIE INC. | $5,600.00 | 10/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201954736 | CMS |
| Incyte Corporation | $1,370.00 | 10/01/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226160813 | CMS |
| ABBVIE INC. | $350.00 | 09/23/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201954734 | CMS |
| Incyte Corporation | $2,055.00 | 09/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226029067 | CMS |
| Caris MPI, Inc. | $155.36 | 09/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234280735 | CMS |
| Genmab U.S., Inc. | $4,900.00 | 09/11/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928703 | CMS |
| ABBVIE INC. | $115.00 | 09/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201954730 | CMS |
| ABBVIE INC. | $14.99 | 09/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201954732 | CMS |
| Genentech USA, Inc. | $76.55 | 09/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598477 | CMS |
| Genmab U.S., Inc. | $48.00 | 09/04/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928699 | CMS |
| Genmab U.S., Inc. | $562.97 | 09/04/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928715 | CMS |
| Genmab U.S., Inc. | $293.67 | 09/04/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928719 | CMS |
| Incyte Corporation | $106.66 | 09/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226029133 | CMS |
| Incyte Corporation | $18.26 | 09/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226029169 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $54.55 | 09/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246120994 | CMS |
| Genmab U.S., Inc. | $70.89 | 09/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928656 | CMS |
| Incyte Corporation | $3,767.50 | 08/26/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226168561 | CMS |
| Genentech USA, Inc. | $89.42 | 08/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598473 | CMS |
| Genentech USA, Inc. | $4,209.45 | 08/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598457 | CMS |
| Genentech USA, Inc. | $50.40 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598461 | CMS |
| Genentech USA, Inc. | $26.24 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598465 | CMS |
| Genentech USA, Inc. | $40.08 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598469 | CMS |
| Genentech USA, Inc. | $21.95 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598421 | CMS |
| Genentech USA, Inc. | $5,871.95 | 08/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598426 | CMS |
| Genentech USA, Inc. | $96.46 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598430 | CMS |
| Genentech USA, Inc. | $474.44 | 08/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598435 | CMS |
| Genentech USA, Inc. | $38.14 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598439 | CMS |
| Genentech USA, Inc. | $32.05 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598443 | CMS |
| Genentech USA, Inc. | $88.79 | 08/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598447 | CMS |
| Genentech USA, Inc. | $521.61 | 08/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598451 | CMS |
| Genentech USA, Inc. | $209.93 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598454 | CMS |
| BeOne Medicines USA, Inc. | $3,600.00 | 08/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202902364 | CMS |
| Genmab U.S., Inc. | $650.00 | 08/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928652 | CMS |
| Incyte Corporation | $3,082.50 | 08/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226033529 | CMS |
| AstraZeneca UK Limited | $2,460.00 | 08/05/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202936518 | CMS |
| Incyte Corporation | $1,027.50 | 07/31/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226169551 | CMS |
| PFIZER INC. | $360.00 | 07/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231673788 | CMS |
| Genentech USA, Inc. | $48.71 | 07/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211598411 | CMS |
| E.R. Squibb & Sons, L.L.C. | $65.00 | 07/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223256548 | CMS |
| ABBVIE INC. | $700.00 | 07/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201954728 | CMS |
| Genmab U.S., Inc. | $3,900.00 | 07/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928648 | CMS |
| ABBVIE INC. | $122.66 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201954724 | CMS |
| ABBVIE INC. | $45.10 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201954726 | CMS |
| Celgene Corporation | $42.38 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184949084 | CMS |
| Genmab U.S., Inc. | $91.94 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928633 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $103.95 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246123353 | CMS |
| Genmab U.S., Inc. | $39.94 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928641 | CMS |
| Genmab U.S., Inc. | $31.71 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235928645 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $18.82 | 1 |
| PY2025 | Principal investigator | $1,210,323.77 | 88 |
| PY2024 | Recipient | $6,362.90 | 2 |
| PY2024 | Principal investigator | $1,298,881.69 | 87 |
| PY2023 | Recipient | $1,199.70 | 1 |
| PY2023 | Principal investigator | $75,790.90 | 11 |
| PY2022 | Principal investigator | $71,092.92 | 12 |
| PY2021 | Principal investigator | $99,041.67 | 19 |
| PY2020 | Principal investigator | $19,967.50 | 2 |
| PY2019 | Principal investigator | $1,762.50 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
89 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $144.00 | 12/31/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting | No dispute reported | 06/30/2026 | 1202533029 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $54,684.06 | 12/31/2025 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar | No dispute reported | 06/30/2026 | 1232928469 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $54,684.06 | 12/31/2025 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar | No dispute reported | 06/30/2026 | 1232928682 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,719.50 | 12/22/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175428499 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 12/22/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175428687 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,000.00 | 12/19/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) | No dispute reported | 06/30/2026 | 1185544402 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 12/18/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202428553 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,446.00 | 12/17/2025 | Non-covered Recipient Entity Exigent Research Llc | A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1235997423 |
| Principal investigator 1 | Incyte Corporation | $396.00 | 12/12/2025 | Non-covered Recipient Entity MISSION CANCER BLOOD JOHN STODDARD CANCER CENTER | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) | No dispute reported | 06/30/2026 | 1240557953 |
| Principal investigator 1 | ABBVIE INC. | $17,150.40 | 12/04/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202528598 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 12/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202428512 |
| Principal investigator 1 | Genentech, Inc. | $3,700.00 | 12/01/2025 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy | No dispute reported | 06/30/2026 | 1211561568 |
| Principal investigator 1 | Genentech, Inc. | $41,255.00 | 12/01/2025 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy | No dispute reported | 06/30/2026 | 1211561572 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 11/10/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175428187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $49,373.55 | 11/07/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175428467 |
| Principal investigator 1 | ABBVIE INC. | $1,540.50 | 11/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202428503 |
| Principal investigator 1 | ABBVIE INC. | $12,359.25 | 11/04/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202520599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 10/27/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175428338 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 10/22/2025 | Non-covered Recipient Entity MISSION CANCER BLOOD JOHN STODDARD CANCER CENTER | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) | No dispute reported | 06/30/2026 | 1240557959 |
| Principal investigator 1 | ABBVIE INC. | $357.50 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202428501 |
| Principal investigator 1 | ABBVIE INC. | $2,405.00 | 09/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202428422 |
| Principal investigator 1 | BeOne Medicines Ltd. | $33,536.00 | 09/08/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190344266 |
| Principal investigator 1 | ABBVIE INC. | $19,098.45 | 09/03/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202508108 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $29,943.60 | 08/31/2025 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar | No dispute reported | 06/30/2026 | 1232928471 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $29,943.60 | 08/31/2025 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar | No dispute reported | 06/30/2026 | 1232928684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $70,974.35 | 08/21/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428208 |
| Principal investigator 1 | Eli Lilly and Company | $6,123.00 | 08/20/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187882038 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,720.00 | 08/18/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342221 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,686.00 | 08/18/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428377 |
| Principal investigator 1 | Eli Lilly and Company | $15,400.00 | 08/12/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD PLLC | A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR | No dispute reported | 06/30/2026 | 1187885018 |
| Principal investigator 1 | Genentech, Inc. | $95,172.00 | 08/11/2025 | Covered Recipient Teaching Hospital University Of Iowa Hosp & Clinics | Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy | No dispute reported | 06/30/2026 | 1211561563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 08/08/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428653 |
| Principal investigator 1 | ABBVIE INC. | $6,228.90 | 08/06/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202428353 |
| Principal investigator 1 | ABBVIE INC. | $2,925.00 | 08/06/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202428357 |
| Principal investigator 1 | ABBVIE INC. | $7,913.70 | 08/06/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202502302 |
| Principal investigator 1 | ABBVIE INC. | $2,692.30 | 07/02/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202428284 |
| Principal investigator 1 | ABBVIE INC. | $10,770.30 | 07/02/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202495091 |
| Principal investigator 1 | Incyte Corporation | $124.50 | 07/02/2025 | Non-covered Recipient Entity MISSION CANCER BLOOD JOHN STODDARD CANCER CENTER | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) | No dispute reported | 06/30/2026 | 1240557947 |
| Recipient | ABBVIE INC. | $18.82 | 06/16/2025 | Covered Recipient Physician | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE2122FL-2) | No dispute reported | 06/30/2026 | 1202398596 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 06/11/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330383 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 06/10/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337050 |
| Principal investigator 1 | ABBVIE INC. | $43,079.85 | 06/03/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202487369 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,227.60 | 06/02/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428568 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,720.00 | 05/28/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336762 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 05/19/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604705 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,650.00 | 05/19/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175428637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 05/15/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175428228 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 05/08/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175428182 |
| Principal investigator 1 | ABBVIE INC. | $5,384.60 | 05/07/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202428112 |
| Principal investigator 1 | ABBVIE INC. | $4,496.85 | 05/07/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202482747 |
| Principal investigator 1 | ABBVIE INC. | $16,852.05 | 05/07/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202482819 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,249.50 | 05/01/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428723 |
| Principal investigator 1 | Genentech, Inc. | $1,250.00 | 04/28/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604698 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 04/28/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604700 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 04/28/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604709 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 04/28/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604722 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 04/28/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604726 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 04/28/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604733 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,605.72 | 04/24/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $550.00 | 04/21/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428699 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 04/16/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323594 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 04/07/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Borte | No dispute reported | 06/30/2026 | 1175428552 |
| Principal investigator 1 | ABBVIE INC. | $5,384.60 | 04/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF IOWA HOSP & CLINICS | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202427979 |
| Principal investigator 1 | ABBVIE INC. | $12,653.55 | 04/03/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202468880 |
| Principal investigator 1 | ABBVIE INC. | $3,142.00 | 04/03/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202474271 |
| Principal investigator 1 | Genentech, Inc. | $1,800.00 | 03/24/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211604678 |
| Principal investigator 1 | BeiGene, Ltd. | $62,880.00 | 03/20/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323844 |
| Principal investigator 1 | ABBVIE INC. | $21,022.20 | 03/11/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202462533 |
| Principal investigator 1 | Eli Lilly and Company | $476.35 | 03/10/2025 | Non-covered Recipient Entity QCCA NETWORK, LLC | A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR | No dispute reported | 06/30/2026 | 1187888214 |
| Principal investigator 1 | ABBVIE INC. | $2,510.30 | 03/07/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202461565 |
| Principal investigator 1 | ABBVIE INC. | $10,951.20 | 03/07/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202461573 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,000.00 | 03/07/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175428612 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 03/06/2025 | Non-covered Recipient Entity DES MOINES ONCOLOGY RESEARCH ASSOCIATION | M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202458367 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,000.00 | 03/06/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175428400 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,000.00 | 03/06/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175428591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 02/24/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428434 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 02/24/2025 | Non-covered Recipient Entity EXIGENT RESEARCH LLC | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175428544 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 02/19/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321932 |
| Principal investigator 1 | ABBVIE INC. | $455.00 | 02/13/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202451315 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 02/12/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190325446 |
| Principal investigator 1 | ABBVIE INC. | $2,510.30 | 02/06/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202448407 |
| Principal investigator 1 | ABBVIE INC. | $10,222.20 | 02/06/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202448575 |
| Principal investigator 1 | ABBVIE INC. | $40,195.60 | 02/06/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202448579 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 01/21/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202440405 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 01/20/2025 | Non-covered Recipient Entity MISSION CANCER AND BLOOD | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323810 |
| Principal investigator 1 | ABBVIE INC. | $5,427.00 | 01/15/2025 | Non-covered Recipient Entity MISSION CANCER + BLOOD | M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202438717 |
| Principal investigator 1 | ABBVIE INC. | $96.00 | 01/07/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202436988 |
| Principal investigator 1 | Celgene Corporation | $20,964.48 | 01/03/2025 | Non-covered Recipient Entity Exigent Research Llc | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222307039 |
| Principal investigator 1 | ABBVIE INC. | $2,510.30 | 01/02/2025 | Non-covered Recipient Entity MISSION CANCER PLUS BLOOD PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202434887 |